{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:58:23Z","timestamp":1791907103302,"version":"4.3.4"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>NUT carcinoma (NC) is a rare and highly aggressive malignancy with a dismal prognosis and a median survival of 6\u20139 months only. Although very few cases of NC are reported each year, the true prevalence is estimated to be much higher, with NC potentially widely underdiagnosed due to the lack of awareness. NC primarily occurs in midline structures including thorax, head, and neck; however, other sites such as pancreas and kidney are also affected, albeit at lower frequencies. NC is characterized by a single translocation involving the <jats:italic>NUTM1<\/jats:italic> (NUT midline carcinoma family member\u00a01) gene and different partner genes. The resulting fusion proteins initiate tumorigenesis through a mechanism involving BET (bromo-domain and extra-terminal motif) proteins such as Bromodomain-containing protein 4 (BRD4) and inordinate acetylation of chromatin, leading to the dysregulation of growth and differentiation genes. While no clinical characteristics are specific for NC, some histologic features can be indicative; therefore, patients with these tumor characteristics should be routinely tested for NUTM1. The diagnosis of NC using immunohistochemistry with a highly specific antibody is straightforward. There are currently no standard-of-care treatment options for patients with NC. However, novel therapies specifically addressing the unique tumorigenic mechanism are under investigation, including BET inhibitors. This review aims to raise awareness of this underdiagnosed cancer entity and provide all patients the opportunity to be properly diagnosed and referred to a clinical study.<\/jats:p>","DOI":"10.3389\/fonc.2022.914031","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T04:39:47Z","timestamp":1658810387000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":56,"title":["NUT Carcinoma\u2014An Underdiagnosed Malignancy"],"prefix":"10.3389","volume":"12","author":[{"given":"Ulrich M.","family":"Lauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Hinterleitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Horger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul V.","family":"Ohnesorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Zender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"B1","article-title":"Novel t(15;19)(q15;p13) Chromosome Abnormality in a Thymic Carcinoma","volume":"51","author":"Kubonishi","year":"1991","journal-title":"Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010901)92:5<1195::aid-cncr1438>3.0.co;2-3","article-title":"Upper Respiratory Tract Carcinoma With Chromosomal Translocation 15;19: Evidence for a Distinct Disease Entity of Young Patients With a Rapidly Fatal Course","volume":"92","author":"Vargas","year":"2001","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931001)72:7<2273::aid-cncr2820720735>3.0.co;2-u","article-title":"Disseminated Mediastinal Carcinoma With Chromosomal Translocation (15;19). A Distinctive Clinicopathologic Syndrome","volume":"72","author":"Lee","year":"1993","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1702086114","article-title":"Ectopic Protein Interactions Within BRD4-Chromatin Complexes Drive Oncogenic Megadomain Formation in NUT Midline Carcinoma","volume":"114","author":"Alekseyenko","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0014","article-title":"NSD3-NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism","volume":"4","author":"French","year":"2014","journal-title":"Cancer Discovery"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210852","article-title":"BRD-NUT Oncoproteins: A Family of Closely Related Nuclear Proteins That Block Epithelial Differentiation and Maintain the Growth of Carcinoma Cells","volume":"27","author":"French","year":"2008","journal-title":"Oncogene"},{"key":"B7","article-title":"BRD4-NUT Fusion Oncogene: A Novel Mechanism in Aggressive Carcinoma","volume":"63","author":"French","year":"2003","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22838","article-title":"Emerging Entities in NUTM1-Rearranged Neoplasms","volume":"59","author":"McEvoy","year":"2020","journal-title":"Genes Chrom Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28060381","article-title":"NUTM1-Rearranged Neoplasms-A Heterogeneous Group of Primitive Tumors With Expanding Spectrum of Histology and Molecular Alterations-An Updated Review","volume":"28","author":"Luo","year":"2021","journal-title":"Curr Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1186\/s12885-021-08432-0","article-title":"Incidence of NUT Carcinoma in Western Australia From 1989 to 2014: A Review of Pediatric and Adolescent Cases From Perth Children's Hospital","volume":"21","author":"Carter","year":"2021","journal-title":"BMC Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21761","article-title":"Cytopathologic Features of NUT Midline Carcinoma: A Series of 26 Specimens From 13 Patients","volume":"124","author":"Bishop","year":"2016","journal-title":"Cancer Cytopathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2350\/09-10-0727-CR.1","article-title":"NUT Midline Carcinoma in a Newborn With Multiorgan Disseminated Tumor and a 2-Year-Old With a Pancreatic\/Hepatic Primary","volume":"13","author":"Shehata","year":"2010","journal-title":"Pediatr Dev Pathol"},{"key":"B13","first-page":"A","article-title":"Unbekannter Prim\u00e4rtumor: Metastasen Aus Dem Nirgendwo","volume":"116","author":"Schenk","year":"2019","journal-title":"Dtsch Arztebl"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000001774","article-title":"Misleading Germ Cell Phenotype in Pulmonary NUT Carcinoma Harboring the ZNF532-NUTM1 Fusion","volume":"46","author":"Agaimy","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1153","article-title":"Clinicopathologic Features and Long-Term Outcomes of NUT Midline Carcinoma","volume":"18","author":"Bauer","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30242","article-title":"Intensive Treatment and Survival Outcomes in NUT Midline Carcinoma of the Head and Neck","volume":"122","author":"Chau","year":"2016","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz094","article-title":"An Anatomical Site and Genetic Based Prognostic Model for Patients With NUT Midline Carcinoma: Analysis of 124 Patients","volume":"4","author":"Chau","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20755","article-title":"Successful Treatment of a Child With T(15;19)-Positive Tumor","volume":"49","author":"Mertens","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ebaa20","article-title":"Long-Term Survival of a Patient With Squamous Cell Carcinoma Harboring NUT Gene Rearrangement","volume":"5","author":"Fujioka","year":"2010","journal-title":"J Thorac Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"P158","DOI":"10.1055\/s-0038-1633780","article-title":"Sinonasal Nuclear Protein Testis Midline Carcinoma: Case Report With a Review of the Literature","volume":"79","author":"Le","year":"2018","journal-title":"J Neurol Surg B"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-013-0428-1","article-title":"The Importance of Diagnosing NUT Midline Carcinoma","volume":"7","author":"French","year":"2013","journal-title":"Head Neck Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw686","article-title":"Complex Chromosomal Rearrangements by Single Catastrophic Pathogenesis in NUT Midline Carcinoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/pin.12727","article-title":"NUT Carcinoma: Clinicopathologic Features, Pathogenesis, and Treatment","volume":"68","author":"French","year":"2018","journal-title":"Pathol Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1433065100","article-title":"The Double Bromodomain Protein Brd4 Binds to Acetylated Chromatin During Interphase and Mitosis","volume":"100","author":"Dey","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1101\/gad.267583.115","article-title":"The Oncogenic BRD4-NUT Chromatin Regulator Drives Aberrant Transcription Within Large Topological Domains","volume":"29","author":"Alekseyenko","year":"2015","journal-title":"Genes Dev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.13.12401","article-title":"Demystifying NUT Midline Carcinoma: Radiologic and Pathologic Correlations of an Aggressive Malignancy","volume":"203","author":"Bair","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-013-0479-3","article-title":"NUT Midline Carcinoma: A Case Report With a Novel Translocation and Review of the Literature","volume":"8","author":"Mills","year":"2014","journal-title":"Head Neck Pathol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1055\/a-1026-6561","article-title":"Nuclear Protein in Testis (NUT) Midline Carcinoma","volume":"192","author":"Baumgartner","year":"2019","journal-title":"Fortschr R\u00f6ntgenstr"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S173056","article-title":"NUT Midline Carcinoma of the Head and Neck: Current Perspectives","volume":"12","author":"Napolitano","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00247-011-2288-8","article-title":"Radiologic Features of NUT Midline Carcinoma in an Adolescent","volume":"42","author":"Rosenbaum","year":"2012","journal-title":"Pediatr Radiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/dc.21134","article-title":"Cytology of Head and Neck Squamous Cell Carcinoma Variants","volume":"38","author":"Chute","year":"2010","journal-title":"Diagn Cytopathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318258f03b","article-title":"Pathologic Characteristics of NUT Midline Carcinoma Arising in the Mediastinum","volume":"36","author":"Evans","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318198d666","article-title":"Diagnosis of NUT Midline Carcinoma Using a NUT-Specific Monoclonal Antibody","volume":"33","author":"Haack","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.09.017","article-title":"Introduction to 2021 WHO Classification of Thoracic Tumors","volume":"17","author":"Tsao","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.107","article-title":"Midline Carcinoma of Children and Young Adults With NUT Rearrangement","volume":"22","author":"French","year":"2004","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"152347","DOI":"10.1016\/j.prp.2019.01.043","article-title":"NUT Carcinoma in a Nutshell: A Diagnosis to be Considered More Frequently","volume":"215","author":"Albrecht","year":"2019","journal-title":"Pathol Res Pract"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2007.052902","article-title":"Demystified Molecular Pathology of NUT Midline Carcinomas","volume":"63","author":"French","year":"2010","journal-title":"J Clin Pathol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2017.1363839","article-title":"Pediatric NUT-Midline Carcinoma: Therapeutic Success Employing a Sarcoma Based Multimodal Approach","volume":"34","author":"Storck","year":"2017","journal-title":"Pediatr Hematol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0358","article-title":"Pediatric NUT Carcinoma is a Rare and Challenging Tumor: Single Center Experience of Five Children","volume":"24","author":"Prasad","year":"2019","journal-title":"Oncologist"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000001046","article-title":"NUT Carcinoma of the Salivary Glands: Clinicopathologic and Molecular Analysis of 3 Cases and a Survey of NUT Expression in Salivary Gland Carcinomas","volume":"42","author":"Agaimy","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-018-4882-y","article-title":"Patterns of Care and Impact of Prognostic Factors in the Outcome of NUT Midline Carcinoma: A Systematic Review and Individual Patient Data Analysis of 119 Cases","volume":"275","author":"Giridhar","year":"2018","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/mph.0000000000001865","article-title":"NUT Carcinoma Without Upfront Surgical Resection: A Case Report","volume":"43","author":"Leeman","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102826","article-title":"NUT Midline Carcinoma: Current Concepts and Future Perspectives of a Novel Tumour Entity","volume":"144","author":"Salati","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25350","article-title":"Histone Deacetylase Inhibitor for NUT Midline Carcinoma","volume":"62","author":"Maher","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3513","article-title":"Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming","volume":"71","author":"Schwartz","year":"2011","journal-title":"Cancer Res"},{"key":"B46","unstructured":"Open Label, Multi-Center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced\/Relapsed Solid Tumors2014"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nature09504","article-title":"Selective Inhibition of BET Bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.2292","article-title":"Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors","volume":"36","author":"Lewin","year":"2018","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors","volume":"4","author":"Piha-Paul","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"B50","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/ijc.33861","article-title":"Safety, Pharmacokinetic, Pharmacodynamic and Clinical Activity of Molibresib for the Treatment of Nuclear Protein of the Testis Carcinoma and Other Cancers: Results of a Phase I\/II Open-Label, Dose Escalation Study","volume":"150","author":"Cousin","year":"2021","journal-title":"Int J Cancer"},{"key":"B51","unstructured":"Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma2018"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01180-1","article-title":"A Phase 1 Study of RO6870810, a Novel Bromodomain and Extra-Terminal Protein Inhibitor, in Patients With NUT Carcinoma, Other Solid Tumours, or Diffuse Large B-Cell Lymphoma","volume":"124","author":"Shapiro","year":"2021","journal-title":"Br J Cancer"},{"key":"B53","unstructured":"An Open Label, Phase Ia\/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit2015"},{"key":"B54","article-title":"Phase I Dose-Finding Study of a Novel Bromodomain and Extra-Terminal Domain (BET) Inhibitor (BI 894999) in Patients (Pts) With Advanced Malignancies. 2018","volume-title":"Presented at the 30th EORTC-NCI-AACR Symposium: Molecular Cancer and Target Therapeutics, 13th\u201316th Nov 2018","author":"Bechter","year":""},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nature24028","article-title":"Discovery of a Selective Catalytic P300\/CBP Inhibitor That Targets Lineage-Specific Tumours","volume":"550","author":"Lasko","year":"2017","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-21-0649","article-title":"miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4","volume":"81","author":"Gen","year":"2021","journal-title":"Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101184","article-title":"Genomic Profiling of Solid Tumors Harboring BRD4-NUT and Response to Immune Checkpoint Inhibitors","volume":"14","author":"Riess","year":"2021","journal-title":"Transl Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13023-020-01449-x","article-title":"Clinical Features, Treatment, and Survival Outcome of Primary Pulmonary NUT Midline Carcinoma","volume":"15","author":"Xie","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.690115","article-title":"Immunotherapy and Targeting the Tumor Microenvironment: Current Place and New Insights in Primary Pulmonary NUT Carcinomaa","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0150-2","article-title":"The Novel BET Bromodomain Inhibitor BI 894999 Represses Super-Enhancer-Associated Transcription and Synergizes With CDK9 Inhibition in AML","volume":"37","author":"Gerlach","year":"2018","journal-title":"Oncogene"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.914031\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T04:39:53Z","timestamp":1658810393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.914031\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":60,"alternative-id":["10.3389\/fonc.2022.914031"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.914031","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"article-number":"914031"}}